Список проголосовавших за комментарий " On The Wires<ul><li>Albemarle Corporation (<strong>ALB</strong>) announced that it intends to redeem all of its outstanding 3.000% Senior Notes due 2019 (CUSIP No. 012725AB3, ISIN No. US012725AB30) issued by it on February 10, 2017. The Notes will be redeemed at a redemption price equal to the greater of (1) 100% of the principal amount of the Notes and (2) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes from the Redemption Date through the Par Call Date, as defined in the Notes, in each case discounted to the date of redemption on a semi-annual basis at the Treasury Rate plus 25 basis points, plus in each case, accrued and unpaid interest on the Notes redeemed to, but not including, the Redemption Date.</li><li>CytoDyn Inc. (<strong>CYDY</strong>) announced the Company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a treatment for HIV-1 infection in treatment-experienced patients with virologic failure. Based on results from four completed and ongoing clinical trials, the Company believes the PRO 140 treatment option addresses the unmet medical need for therapy options for HIV-1 infected patients with uncontrolled viral load, despite conventional Antiretroviral Therapy.</li><li>WEX (<strong>WEX</strong>) announced that it has signed a new agreement with Enterprise Fleet Management in Canada. The partnership supports Enterprise's growth in the Canadian market through WEX's Canadian fleet capabilities.</li><li>B Communications Ltd. (<strong>BCOM</strong>) announced a private placement of NIS 118,000,000 par value of its Series C Debentures to Israeli institutional investors for an aggregate consideration of approximately NIS 118 million (approximately US$ 31 million).</li></ul>"